Quick Answer
Outlook Therapeutics, Inc. reported Cash and Equivalents of $8.08 million for fiscal year 2025.
Outlook Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.08M | -45.9% |
| 2024 | $14.93M | -36.2% |
| 2023 | $23.39M | +34.5% |
| 2022 | $17.40M | +20.2% |
| 2021 | $14.48M | +15.5% |
| 2020 | $12.54M | +56.4% |
| 2019 | $8.02M | +366.7% |
| 2018 | $1.72M | -46.1% |
| 2017 | $3.19M | +35.4% |
| 2016 | $2.35M | -74.1% |
| 2015 | $9.07M | +286.1% |
| 2014 | $2.35M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $8.68M | +52.2% | +7.4% |
| September 30, 2025 | $8.08M | -45.9% | -9.2% |
| June 30, 2025 | $8.90M | -72.2% | +17.8% |
| March 31, 2025 | $7.56M | -84.0% | +32.5% |
| December 31, 2024 | $5.70M | -44.9% | -61.8% |
| September 30, 2024 | $14.93M | -36.2% | -53.4% |
| June 30, 2024 | $32.02M | -5.0% | -32.2% |
| March 31, 2024 | $47.23M | +8.3% | +356.0% |
- Outlook Therapeutics, Inc. showed a decrease of -45.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Outlook Therapeutics, Inc.’s cash and equivalents has grown by 244.1% (from $2.35 million to $8.08 million).
- The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: